Journal list menu
An Exciting Partnership!
Advances in Cell and Gene Therapy will become part of a partnership between Wiley and Hindawi and is fully open access. Advances in Cell and Gene Therapy will remain a Wiley title but will be published and hosted by Hindawi and will benefit from Hindawi’s experience and expertise in publishing open access titles. Advances in Cell and Gene Therapy will continue to undergo a rigorous peer review process ensuring that quality remains high. Manuscripts published after January 1, 2022 will be published as open access articles, making them immediately free to read, download and share. Authors or their funder will be required to pay an Article Publication Charge upon acceptance. For further information, click here.
About This Journal
Advances in Cell and Gene Therapy is an international journal publishing original, high-quality, peer-reviewed articles which cover basic and clinical research relating to advances in cell, gene, and immune therapies and their use in the treatment of nonmalignant and neoplastic hematological diseases, as well as some non-hematological diseases. The topics the journal covers include hematopoietic cell transplants and cell, gene and immune therapies in children and adults with a wide range of disorders, including cancers, genetic and immune diseases. All articles include a section or feature detailing the current and future clinical implications of the research. Among the extensive provocative Reviews, Case Reports, and Expert Commentaries, Advances in Cell and Gene Therapy provides a forum for presenting Original Research Articles and sharing ideas for innovation, as well as disseminating knowledge of primary clinical relevance to advance patient care.
On the Cover
-  20 October 2021
Identification of homologous human miRNAs as antivirals towards COVID‐19 genome
-  13 September 2021
Immunological tumor heterogeneity and diagnostic profiling for advanced and immune therapies
-  25 June 2021
Inhospital morbidity and mortality among acute myeloid leukemia patients admitted for hematopoietic stem cell transplantation between 2002‐2017
-  15 May 2021
An in silico analysis of effective siRNAs against COVID‐19 by targeting the leader sequence of SARS‐CoV‐2
-  12 February 2021
Advances in Cell and Gene Therapy is an international journal publishing original, high-quality, peer reviewed articles which cover basic and clinical research relating to advances in cell, gene, and immune therapies, and their use in the treatment of nonmalignant and neoplastic hematological diseases, as well as some non-hematological diseases. The goal of Advances in Cell and Gene Therapy is to become a source for easily comprehendible, unbiased, accurate and up-to-date studies and reviews about the field, along with provocative commentaries from internationally renowned experts. Given the rapid positive advances in the field of cell and gene therapies and the explosive growth of immunotherapy for nonmalignant and neoplastic disorders, the journal's content will be useful for readers worldwide.
The journal will be a robust, engaging tool to aid vital activities in daily work settings - each article will include a clinical/scientific implications section that indicates the practical relevance of the research to clinicians in the field. Please visit the journal's Aims & Scope and Author Guidelines pages for further information.
The Journal has an extensive, internationally renowned Editorial team, consisting of experts within the field of cell and gene therapy who work alongside the Editors-in-Chief. For the full list, please visit the Editorial Board page.
Meet the Editors-in-Chief
Dr. Syed A. Abutalib earned his medical degree from Dow Medical College in Karachi, Pakistan. He subsequently completed an internal medical residency with emphasis on hematologic malignancies at Cook County Hospital in Chicago and a fellowship in hematology/oncology at the University of Illinois at Chicago (UIC), with an emphasis on blood and bone marrow transplantation. Dr. Abutalib is Assistant Director of the Hematology and Transplant Program at Cancer Treatment Centers of America© (CTCA) at Midwestern and co-leader for the CTCA enterprise-wide Hematologic Malignancies Cancer Institute, in addition to his role as Clinical Director for the Hematopoietic Cell Collection Facility.
Dr. Abutalib has co-edited ten Hematology and Bone Marrow Transplant books over a short span of 4 years and has published in a number of cancer magazines, journal, and textbooks. Dr. Abutalib continues to collaborate with other experts worldwide in the area of hematology/oncology and transplantation to explore and develop innovative ideas and breakthroughs in Medical Education with a primary focus on improvement of patient care. Dr. Abutalib is the Founding Editor of Advances in Cell and Gene Therapy.
Dr. Rupert Handgretinger earned his medical degree from the University of Tübingen, Germany. He completed a pediatric medical residency with an emphasis on hematology/oncology at the Children's University Hospital Tübingen, where he also completed his fellowship in pediatric hematology/oncology, with an emphasis on allogeneic, and especially haploidentical, transplantation. After his fellowship, he became the director of the stem cell laboratory at the same hospital, where he was involved in the development and clinical applications of new graft-engineering techniques.
In 2000, he was appointed the Director of the Division of Stem Cell Transplantation at the St. Jude Children's Research Hospital in Memphis, USA, where he also served as the director of the stem cell laboratory, and as a full faculty member and Professor of Pediatrics at the University of Tennessee, Memphis. In 2010, Dr. Handgretinger was appointed the Medical Director of the Children's University Hospital in Tübingen. Dr. Handgretinger's main research interests are cellular immunotherapeutic approaches to the treatment of children and adults with various forms of cancer. Dr. Handgretinger has published and co-published over 400 articles in the field of pediatric hematology/oncology and allogeneic stem cell transplantation.
The following is a list of the most cited articles based on citations published in the last three years, according to CrossRef.
TRUCKS, the fourth‐generation CAR T cells: Current developments and clinical translation
-  24 April 2020
CAR T cells targeting αvβ3 integrin are effective against advanced cancer in preclinical models
-  10 July 2018
Toward “off‐the‐shelf” allogeneic CAR T cells
-  30 April 2020
CD276 as a novel CAR NK‐92 therapeutic target for neuroblastoma
-  19 October 2020
Rapid production of clinical‐grade SARS‐CoV‐2 specific T cells
-  12 July 2020